| Literature DB >> 32779521 |
Jae-Won Hyun1, Hye Lim Lee2, Woo Kyo Jeong3, Hye Jung Lee3, Jong Hwa Shin3, Ju-Hong Min3, Byoung Joon Kim3, Seung Woo Kim4, Ha Young Shin4, Jeeyoung Oh5, Woojun Kim6, Hyun-June Shin7, Sun-Young Oh7, Hyunjin Kim8, Young-Min Lim8, So-Young Huh9, Eun Bin Cho10, Tai-Seung Nam11, Seung-Han Lee11, Sun-Young Kim12, Sa-Yoon Kang13, Suk Geun Han14, Eun Hee Sohn15, Seol-Hee Baek16, Byung-Jo Kim16, Sang-Soo Lee17, Jin Myoung Seok18, Yoon-Ho Hong19, Seong-Il Oh20, Jong Kuk Kim21, Kyong Jin Shin22, Ohyun Kwon23, Joong-Yang Cho24, Jong Seok Bae25, So Yeon Kim26, Yeseul Kim26, Min Young Lee1, Su-Hyun Kim1, Ho Jin Kim27.
Abstract
We aimed to compare seroprevalence of anti-myelin oligodendrocyte glycoprotein (MOG) and anti-aquaporin-4 (AQP4) antibodies in Korean adults with inflammatory demyelinating diseases (IDDs) of the central nervous system (CNS), based on a multicenter nationwide database. Sera were analyzed using a live cell-based assay for MOG and AQP4 antibodies. Of 586 Korean adults with IDDs of the CNS, 36 (6.1%) and 185 (31.6%) tested positive for MOG and AQP4 antibodies, respectively. No participant showed double positivity. Seroprevalence of MOG antibodies was about five times lower than that of AQP4 antibodies in a large cohort of Korean adults with IDDs of the CNS.Entities:
Keywords: Aquaporin-4; adult; myelin oligodendrocyte glycoprotein; prevalence
Year: 2020 PMID： 32779521 DOI： 10.1177/1352458520948213
Source DB: PubMed Journal: Mult Scler ISSN： 1352-4585 Impact factor: 6.312